5,407 results match your criteria Lymphoma Mantle Cell


Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.

Drugs R D 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, 93-510, Lodz, Poland.

Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity. It exerts its anti-neoplastic action mainly via the inhibition of the nuclear factor-κB pathway components associated with cell proliferation, apoptosis, and angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40268-019-0269-9DOI Listing

Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report.

BMC Cancer 2019 Apr 15;19(1):355. Epub 2019 Apr 15.

Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) that often affects men over the age of 60. Systemic metastasis of MCL to eyes is rare and intraocular involvement is even rarer, which usually affects the choroid and iris. To the best of our knowledge, ciliary body metastasis of systemic MCL has not been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5530-7DOI Listing

A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma.

Hematol Oncol 2019 Apr 15. Epub 2019 Apr 15.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant eligible patients and the optimal approach remains unknown. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2618
Publisher Site
http://dx.doi.org/10.1002/hon.2618DOI Listing
April 2019
1 Read

Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.

Cancer Med 2019 Apr 13. Epub 2019 Apr 13.

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Red blood cell distribution width (RDW), which measures the range of variation of red blood cell volume, has been explored as a prognostic factor in multiple types of cancer. However, the role of RDW in mantle cell lymphoma (MCL), a rare type of non-Hodgkin lymphoma with poor outcomes, remains to be determined. Therefore, we investigated the prognostic role of RDW in MCL. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.2155
Publisher Site
http://dx.doi.org/10.1002/cam4.2155DOI Listing
April 2019
6 Reads

Intraocular involvement of Mantle cell lymphoma: A case report and literature review.

Hematol Oncol Stem Cell Ther 2019 Apr 6. Epub 2019 Apr 6.

Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.

Lymphomatous involvement of the ocular adnexal region (OAR) is generally rare; however, it constitutes the most common ocular malignancy. Most cases of ocular adnexal lymphomas are extra nodal marginal zone B cell lymphomas. Mantle cell lymphoma involvement (MCL) of the OAR is a less common presentation compared with other lymphomas and it has been reported anecdotally. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2019.03.002DOI Listing
April 2019
1 Read

Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated With Up-front Autologous Stem Cell Transplantation.

Appl Immunohistochem Mol Morphol 2019 Apr 9. Epub 2019 Apr 9.

Departments of Hematology.

We report 2 cases of composite lymphoma comprising mantle cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, a rare association that has only been reported twice in the literature. In case 1, a 64-year-old woman presented with massive splenomegaly and lymphadenopathy. Immunohistochemical studies of the lymph node biopsy suggested the presence of 2 lymphomas, a predominant component of a peripheral T-cell lymphoma, not otherwise specified and an in situ mantle cell neoplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000769DOI Listing
April 2019
1 Read

Acalabrutinib for Mantle Cell Lymphoma.

Blood 2019 Apr 9. Epub 2019 Apr 9.

Division of Hematology, Mayo Clinic, United States.

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma (NHL) characterized by the overexpression of cyclin D1. MCL patients typically live years but experience multiple relapses. Acalabrutinib (Acala) is a novel second generation oral Bruton's tyrosine kinase (BTK) inhibitor approved by the US FDA for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019852368DOI Listing
April 2019
3 Reads

The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.

Med Sci Monit 2019 Apr 9;25:2599-2608. Epub 2019 Apr 9.

Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China (mainland).

BACKGROUND Mantle cell lymphoma (MCL) is a high-grade B-cell lymphoma with poor prognosis. Fludarabine is used alone or in combination for relapsed and advanced-stage MCL. The expression of the signal transducer and activator of transcription 5B (STAT5B) gene is associated with tumorigenesis in solid tumors, but its role in MCL remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.914934DOI Listing
April 2019
1 Read

Mantle Cell Lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication and management.

Am J Hematol 2019 Apr 8. Epub 2019 Apr 8.

Anderson Cancer Center, Lymphoma/Myeloma.

Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years. Heterogeneity in the clinical course of MCL - indolent vs. aggressive - is further delineated by a correlation with the mutational status of the variable region of immunoglobulin heavy chain (IGHV), methylation status, and SOX-11 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25487DOI Listing
April 2019
1 Read

Turning Point in the Treatment of Mantle Cell Lymphoma.

Authors:
Toru Motokura

Yonago Acta Med 2019 Mar 28;62(1):1-7. Epub 2019 Mar 28.

Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.

Mantle cell lymphoma (MCL) is an incurable type of B-cell lymphoma. It is typically composed of small-to-medium-sized cleaved lymphoid cells with cyclin D1 protein expression due to the chromosomal translocation t(11;14)(q13;q32). Even with the development of rituximab, an anti-CD20 antibody drug, the long-term outcome of patients with MCL has not improved. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437406PMC
March 2019
3 Reads

Consolidation with Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.

Leuk Lymphoma 2019 Apr 9:1-8. Epub 2019 Apr 9.

h Policlinico "Sant'Orsola-Malpighi" - University of Bologna Institute of Hematology "Seràgnoli" , Bologna , Italy.

Polish Lymphoma Research Group performed a phase-II trial to test whether Y ibritumomab tiuxetan radioimmunotherapy (Y90) may constitute an alternative consolidation for mantle cell lymphoma patients unfit for high-dose therapy. Forty-six patients were consolidated with Y90 following response to the 1st (n = 34) or 2nd line (n = 12) (immuno)chemotherapy. Majority of the patients had advanced disease (stage IV and presence of B-symptoms in 85% and 70%, respectively) and high MIPI (5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1602261DOI Listing
April 2019
1 Read

Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report.

J Cutan Pathol 2019 Apr 8. Epub 2019 Apr 8.

Department of Dermatology, University of Utah, Salt Lake City, Utah.

Secondary cutaneous involvement by mantle cell lymphoma (MCL), an uncommon aggressive B-cell malignancy, predominantly involves the dermis, with few reports of pannicular involvement. Lymphocytic infiltration of subcutaneous tissue is associated with inflammatory panniculitides and certain T-cell lymphomas, primarily subcutaneous panniculitis-like T-Cell lymphoma (SPTCL), which is characterized by rimming of adipocytes by tumor cells. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.13471
Publisher Site
http://dx.doi.org/10.1111/cup.13471DOI Listing
April 2019
7 Reads

The Muddied Waters of Ibrutinib Therapy.

Acta Haematol 2019 Apr 3;141(4):209-213. Epub 2019 Apr 3.

Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel.

A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors. This report includes a review of reported cases of Aspergillus infections in patients receiving ibrutinib and the shared features of these cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496555DOI Listing
April 2019
3 Reads

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.

Leukemia 2019 Apr 2. Epub 2019 Apr 2.

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

The microenvironment strongly influences mantle cell lymphoma (MCL) survival, proliferation, and chemoresistance. However, little is known regarding the molecular characterization of lymphoma niches. Here, we focused on the interplay between MCL cells and the associated monocytes/macrophages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0463-3DOI Listing
April 2019
1 Read

The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma.

J Oncol Pharm Pract 2019 Apr 2:1078155219841110. Epub 2019 Apr 2.

University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Research and Training Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Ankara, Turkey.

Introduction: The aim of this study was to investigate the influence of high-dose cytosine arabinoside (HDAC)-containing treatments followed by autologous hematopoietic stem cell transplantation on the survival of patients with mantle cell lymphoma.

Material And Methods: The data of 27 MCL patients who were followed-up between January 2009 and December 2015 were analyzed retrospectively.

Results: The median age of the patients was 63 (range, 45-82) with 22 (81. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219841110DOI Listing
April 2019
1 Read

Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma.

Cancer Biomark 2019 Mar 22. Epub 2019 Mar 22.

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.

Background: Although risk stratification of mantle cell lymphoma (MCL) is most frequently performed using the simplified MCL International Prognostic Index (sMIPI), the identification of host-related factors and tumor microenvironment, including absolute monocyte counts (AMC) and peripheral blood T lymphocyte subsets, especially absolute natural killer cell counts (ANKC) has been suggested to be critical in the prediction of prognosis and the guidance of treatment.

Objective: This study was aimed at investigating whether peripheral blood ANKC and AMC at diagnosis had an impact on MCL prognosis.

Methods: A total of 92 newly diagnosed MCL patients was enrolled in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-182193DOI Listing
March 2019
1 Read
1.186 Impact Factor

Blastoid variant of mantle cell lymphoma of the female urethra mimicking a caruncle: A rare but highly aggressive subtype case with literature review.

Arch Ital Urol Androl 2019 Mar 29;91(1):49-50. Epub 2019 Mar 29.

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Department of Urology, Milan; University of Milan.

Primary urethral lymphoma is a rare entity without a standardized treatment protocol. We report a case of an elderly woman presenting with a caruncle associated with vaginal spotting and intermittent dysuria. She underwent surgical excision of the lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/aiua.2019.1.49DOI Listing
March 2019
2 Reads

Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.

Chem Pharm Bull (Tokyo) 2019 ;67(4):382-388

School of Biological Science and Technology, University of Jinan.

As an important epigenetics related enzyme, protein arginine methyltransferase 5 (PRMT5) has been confirmed as an anticancer therapeutic target in recent years. Among all the reported PRMT5 inhibitors, two small molecules (GSK-3326595 and JNJ-64619178) are currently being assessed in clinical trial. In this study, 40 PRMT5 inhibitor candidates were purchased from SPECS database supplier according to the pharmacophore and molecular docking based virtual screening results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c18-00980DOI Listing
January 2019
1 Read

Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.

Ann Nucl Med 2019 Mar 30. Epub 2019 Mar 30.

Nuclear Medicine, University of Brescia and Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy.

Objective: Mantle cell lymphoma (MCL) is an aggressive lymphoma sub-type with poor prognosis and high 18F-FDG avidity at PET/CT; nowadays, no validated criteria for PET/CT in treatment response evaluation and prediction of outcome are present. The aim of study was to investigate whether the metabolic PET/CT features may predict treatment evaluation and prognosis in MCL.

Methods: We retrospectively enrolled 87 patients who underwent baseline 18F-FDG PET/CT and 85 end-of-treatment (eot) PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-019-01354-9DOI Listing
March 2019
2 Reads

Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Target Oncol 2019 Apr;14(2):125-138

Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, 455D Wiseman Hall, 410 W 12th Ave, Columbus, OH, 43210, USA.

Inhibitors of Bruton's tyrosine kinase (BTK), a major kinase in the B-cell receptor (BCR) signaling pathway, mediating B-cell proliferation and apoptosis, have substantially altered the management, clinical course, and outcome of patients with B-cell malignancies. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-019-00635-7DOI Listing
April 2019
1 Read

NIK as a Druggable Mediator of Tissue Injury.

Trends Mol Med 2019 Apr 26;25(4):341-360. Epub 2019 Mar 26.

Department of Nephrology and Hypertension, Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, School of Medicine, Universidad Autónoma de Madrid (UAM), Red de Investigación Renal (REDINREN), and Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Madrid, Spain; These authors contributed equally. Electronic address:

NF-κB-inducing kinase (NIK, MAP3K14) is best known as the apical kinase that triggers non-canonical NF-κB activation and by its role in the immune system. Recent data indicate a role for NIK expressed by non-lymphoid cells in cancer, kidney disease, liver injury, glucose homeostasis, osteosarcopenia, vascular calcification, hematopoiesis, and endothelial function. The spectrum of NIK-associated disease now ranges from immunodeficiency (when NIK is defective) to autoimmunity, cancer, sterile inflammation, fibrosis, and metabolic disease when NIK is overactive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2019.02.005DOI Listing
April 2019
2 Reads

Treatment modalities of non-Hodgkin lymphoma patients over 65 years of age: A two-center experience.

J Oncol Pharm Pract 2019 Mar 29:1078155219839460. Epub 2019 Mar 29.

9 Department of Biostatistics and Medical Informatics, Bezmialem Vakif University, Istanbul, Turkey.

Objective: This study was conducted with the aim of making the contribution to a decision for treatment and determination of the modalities in patients diagnosed with non-Hodgkın lymphoma which increasingly become widespread in the geriatric population.

Materials And Methods: Ninety-one patients aged over 65 years diagnosed with lymphoma and treated in Bezmialem Vakıf University Medical Faculty Hospital and Haseki Training and Research Hospital between 2008 and 2013 were retrospectively evaluated. Finally, 63 patients for whom data could be reached were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219839460DOI Listing
March 2019
1 Read

Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8.

J Exp Clin Cancer Res 2019 Mar 29;38(1):138. Epub 2019 Mar 29.

School of Dentistry, University of California, Los Angeles, CA, 90095, USA.

Background: SOX11 is a transcription factor that plays an important role in mantle cell lymphoma development. However, its functional role in head and neck squamous cell carcinoma (HNSCC) remains unknown.

Methods: Protein expression was measured with Western blotting, immunohistochemistry or quantitative proteomics, and gene expression was measured with quantitative RT-PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1146-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440126PMC
March 2019
1 Read

High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.

J Clin Exp Hematop 2019 ;59(1):1-16

The microenvironment influences the behavior of follicular lymphoma (FL) but the specific roles of the immunomodulatory BTLA and TNFRSF14 (HVEM) are unknown. Therefore, we examined their immunohistochemical expression in the intrafollicular, interfollicular and total histological compartments in 106 FL cases (57M/49F; median age 57-years), and in nine relapsed-FL with transformation to DLBCL (tFL). BTLA expression pattern was of follicular T-helper cells (TFH) in the intrafollicular and of T-cells in the interfollicular compartments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3960/jslrt.19003DOI Listing
January 2019
4 Reads

Mantle cell lymphoma presenting with exaggerated skin reaction to insect bites.

BMJ Case Rep 2019 Mar 21;12(3). Epub 2019 Mar 21.

Department of Dermatology, Saint Louis University Hospital, Saint Louis, Missouri, USA.

We present the case of a 62-year-old African-American woman with medical history of hypertension and hyperlipidaemia who presented to dermatology clinic for 'bug bites'. Skin examination showed resolving bullae on the shins and postinflammatory pigment changes. Histopathology showed eosinophilic spongiosis and direct immunofluorescence (DIF) was negative for IgG, IgM, IgA and C3. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22759
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-227590DOI Listing
March 2019
4 Reads

Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).

Expert Opin Ther Pat 2019 Apr;29(4):217-241

a Department of Medicinal Chemistry, School of Pharmacy, Health Science Center , Xi'an Jiaotong University , Xi'an , Shaanxi P.R. China.

Introduction: Bruton's tyrosine kinase (BTK) plays a critical role in the regulation of survival, proliferation, activation and differentiation of B-lineage cells. It participates by regulating multiple cellular signaling pathways, including B cell receptor and FcR signaling cascades. BTK is abundantly expressed and constitutively active in the pathogenesis of B cell hematological malignancies, as well as several autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2019.1594777DOI Listing
April 2019
2 Reads

Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base.

Hematology 2019 Dec;24(1):378-386

b The Warren Alpert Medical School of Brown University , Providence , RI , USA.

Objectives: To examine the use of splenectomy, chemotherapy, and subsequent overall survival (OS) in contemporary patients with splenic lymphomas.

Methods: We analyzed records of 6450 patients with various splenic lymphomas recorded in the National Cancer Data Base (2004-2013). Survival was compared using Mantel-Byer test to account for guarantee-time bias, stratified by age, sex, comorbidities, and lymphoma stage. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425967PMC
December 2019
8 Reads
1.189 Impact Factor

Management of adverse effects/toxicity of ibrutinib.

Authors:
Semra Paydas

Crit Rev Oncol Hematol 2019 Apr 10;136:56-63. Epub 2019 Feb 10.

Cukurova University Faculty of Medicine Dept of Medical Oncology, Adana, Turkey. Electronic address:

Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor (BTKi) and forms an irreversible covalent bound to BTK at the Cysteine-481 residue. Ibrutinib has been approved by FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, marginal zone lymphoma and chronic graft-versus-host disease in allogeneic stem cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2019.02.001DOI Listing
April 2019
1 Read

Colorectal Lymphoma: A Contemporary Case Series.

Dis Colon Rectum 2019 Mar 8. Epub 2019 Mar 8.

Background: Colon and rectal lymphomas are rare and can occur in the context of posttransplant lymphoproliferative disorder. Evidence-based management guidelines are lacking.

Objective: The purpose of this study was to characterize the presentation, diagnosis, and management of colorectal lymphoma and to identify differences within the transplant population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DCR.0000000000001373DOI Listing
March 2019
3 Reads

Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.

Oncol Lett 2019 Mar 28;17(3):3382-3386. Epub 2019 Jan 28.

Department of Cardiothoracic Surgery, Suizhou Central Hospital, Suizhou, Hubei 441300, P.R. China.

The present study explored the significance of programmed death-ligand 1 (PD-L1) molecules in the diagnosis and treatment of B-cell malignant lymphoma. A total of 92 patients with B-cell malignant lymphoma (experimental group), admitted to the Quanzhou First Hospital Affiliated to Fujian Medical University from February 2014 to May 2017, and 60 healthy subjects (control group) were enrolled in this study and their clinical data were retrospectively analyzed. Plasma levels of PD-L1 before treatment and at 5, 10, and 15 days after treatment were measured by ELISA. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2019.9982
Publisher Site
http://dx.doi.org/10.3892/ol.2019.9982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396271PMC
March 2019
3 Reads

Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.

Mol Cancer Res 2019 Mar 12. Epub 2019 Mar 12.

Department of Pathology and School of Medicine, Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania

Current methods to evaluate effects of kinase inhibitors in cancer are suboptimal. Analysis of changes in cancer metabolism in response to the inhibitors creates an opportunity for better understanding of the interplay between cell signaling and metabolism and, from the translational perspective, potential early evaluation of response to the inhibitors as well as treatment optimization. We performed genomic, metabolomic and fluxomic analyses to evaluate the mechanism of action of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in mantle cell lymphoma (MCL) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0256DOI Listing
March 2019
7 Reads

Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.

Bioorg Med Chem Lett 2019 May 5;29(9):1060-1064. Epub 2019 Mar 5.

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 Culture West Road, Jinan 250012, PR China. Electronic address:

Mantle cell lymphoma (MCL) is characterized by the translocation t(11;14) (q13;q32), resulting in the overexpression of cyclin-D1. The progression of MCL is an interaction of multitarget and multilink regulation. It has been proven that Bruton's tyrosine kinase (BTK) is commonly overexpressed in MCL, which makes it a focus of targeted therapy for MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2019.03.005DOI Listing

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Leuk Lymphoma 2019 Mar 8:1-9. Epub 2019 Mar 8.

a Department of Hematology and Oncology, Winship Cancer Institute , School of Medicine, Emory University , Atlanta , GA , USA.

Mantle cell lymphoma (MCL) is a rare cancer with diverse management options. Although clinical practice guidelines have become ubiquitous across medicine, the utility of guidelines for MCL management is limited by provider awareness and the lack of a definitive standard of care. We sought to determine whether expert recommendations, delivered as an online decision support tool, impacted practitioners' therapeutic decisions with MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1574006DOI Listing
March 2019
3 Reads

[Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].

Rev Med Chil 2019 ;147(1):9-17

Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Background: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with rituximab.

Aim: To assess the outcomes of patients with MCL treated in a university hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872019000100009DOI Listing
March 2019
2 Reads

When to use stem cell transplant in mantle cell lymphoma.

Expert Rev Hematol 2019 Mar 7:1-4. Epub 2019 Mar 7.

b Department of Hematology and Medical Oncology , Emory University Winship Cancer Institute , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1588106DOI Listing
March 2019
1 Read

[Metachronous Development of Mantle Cell Lymphoma during Active Surveillance in a Patient with Stage I Testicular Cancer].

Hinyokika Kiyo 2018 Dec;64(12):509-513

The Department of Urology, Faculty of Medicine, University of Tsukuba.

A 78-year-old man presented with swelling of para-aortic and left iliac lymph nodes (LNs). He had undergone left high orchiectomy 10 years ago. He was diagnosed with stage I seminoma, and was managed with active surveillance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_64_12_509DOI Listing
December 2018
1 Read

Pleomorphic Mantle Cell Lymphoma of the Tongue Base Presenting With Dysphagia.

Clin Med Insights Ear Nose Throat 2019 24;12:1179550619831058. Epub 2019 Feb 24.

Division of Head and Neck Surgery & Communication Sciences, Department of Surgery, Duke University, Durham, NC, USA.

Objectives: We aim to increase awareness of pleomorphic mantle cell lymphoma as a rare, but aggressive form of lymphoma with propensity for recurrence in secondary locations.

Methods: We report the case of a 70-year-old man who presented with chronic post-nasal drainage, dysphagia, and voice changes caused by a tongue base mass.

Results: Partial excision and pathology showed a pleomorphic mantle cell lymphoma, and radiation treatment was completed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179550619831058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390209PMC
February 2019
3 Reads

Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Leuk Lymphoma 2019 Mar 1:1-10. Epub 2019 Mar 1.

b Division of Hematology, College of Medicine , The Ohio State University , Columbus , OH , USA.

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy for which novel therapeutics with improved efficacy are greatly needed. To provide support for clinical immune checkpoint blockade, we comprehensively evaluated the expression of therapeutically targetable immune checkpoint molecules on primary MCL cells. MCL cells showed constitutive expression of Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1), variable CD200, absent PD-L2, Lymphocyte Activation Gene 3 (LAG-3), and Cytotoxic T-cell Associated Protein 4 (CTLA-4). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1569231DOI Listing
March 2019
1 Read

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.

JAMA Oncol 2019 Feb 28. Epub 2019 Feb 28.

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee.

Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.6278DOI Listing
February 2019
7 Reads

Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.

Intern Med J 2019 Feb 28. Epub 2019 Feb 28.

Division of Cancer Services, Clinical Haematology, Princess Alexandra Hospital, Brisbane, QLD.

Mantle cell lymphoma (MCL) and the marginal zone lymphoma (MZL) subtypes (nodal MZL, extra-nodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma) and splenic MZL) are uncommon lymphoma subtypes, accounting for less than 5-10% of all non-Hodgkin lymphoma. The evidence base for therapy is therefore limited and enrolment into clinical trials is preferred. Outcomes for patients with MCL have been steadily improving mainly due to the adoption of more intense strategies in younger patients, the use of rituximab maintenance and the recent introduction of bendamustine in older patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14268DOI Listing
February 2019
1 Read

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

J Clin Oncol 2019 Apr 27;37(12):984-991. Epub 2019 Feb 27.

14 US Oncology Research, The Woodlands, TX.

Purpose: The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00605
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00605DOI Listing
April 2019
9 Reads
18.428 Impact Factor

Mantle cell lymphoma of the cecum.

Rev Esp Enferm Dig 2019 Apr;111(4):333-334

Gastroenterology, Hospital Garcia de Orta, Portugal.

The authors have read with great interest the recently published article "Colon lymphomas: an analysis of our experience over the last 23 years" by Martín Domínguez V et al., a single center retrospective review of 29 patients diagnosed with colon lymphoma. The present report describes a case of mantle cell lymphoma (MCL) of the cecum that aims to improve the knowledge regarding this unusual clinical and endoscopic entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17235/reed.2019.5936/2018DOI Listing
April 2019
2 Reads

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Blood 2019 Feb 25. Epub 2019 Feb 25.

University of Michigan, Ann Arbor, MI, United States.

This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in patients with relapsed or refractory B-cell malignancies, alone or in combination with a Janus kinase 1 inhibitor (itacitinib) or chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide). Seventy-two patients received parsaclisib monotherapy (5-45 mg once daily). Expansion doses were 20 and 30 mg once daily; intermittent dosing at 20 mg (once daily for 9 weeks, then once weekly) was explored. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-08
Publisher Site
http://dx.doi.org/10.1182/blood-2018-08-867499DOI Listing
February 2019
9 Reads

Ibrutinib-Associated Serositis in Mantle Cell Lymphoma.

Am J Respir Crit Care Med 2019 Feb 25. Epub 2019 Feb 25.

The University of Texas at MD Anderson Cancer Center, Pulmonary Medicine, Houston, Texas, United States ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201809-1738IMDOI Listing
February 2019
2 Reads
12.996 Impact Factor

Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.

Angew Chem Int Ed Engl 2019 Feb 25. Epub 2019 Feb 25.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer. However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive. Here, we report imide-based degrader molecules capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201901336DOI Listing
February 2019
2 Reads

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: Daratumumab is a CD38 monoclonal antibody approved for treating relapsed/refractory and newly diagnosed multiple myeloma. Preclinical daratumumab studies demonstrated cytotoxic activity and reduced tumor growth in B-cell non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle-cell lymphoma (MCL).

Patients And Methods: This was a phase 2, open-label, multicenter, 2-stage trial. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183128
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.013DOI Listing
January 2019
11 Reads

Metachronous Sigmoid Carcinoma and Mantle Cell Lymphoma in Intestines.

Case Rep Gastroenterol 2019 Jan-Apr;13(1):17-24. Epub 2019 Jan 10.

Department of Pathology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.

It is rare that colon carcinoma and mantle cell lymphoma (MCL) occur one after another in intestines. We found two malignancies of sigmoid carcinoma and MCL in a single patient, who had initially been diagnosed with sigmoid carcinoma and treated with radical resection in our hospital. Good postoperative recovery was reported without recurrence signs, which lasted for 7 years and 5 months until polyps of sigmoid colon were found by colonoscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381904PMC
January 2019
1 Read